Claire Fabre

2.8k total citations
43 papers, 1.3k citations indexed

About

Claire Fabre is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Claire Fabre has authored 43 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Hematology, 17 papers in Molecular Biology and 14 papers in Oncology. Recurrent topics in Claire Fabre's work include Acute Myeloid Leukemia Research (11 papers), Multiple Myeloma Research and Treatments (10 papers) and NF-κB Signaling Pathways (7 papers). Claire Fabre is often cited by papers focused on Acute Myeloid Leukemia Research (11 papers), Multiple Myeloma Research and Treatments (10 papers) and NF-κB Signaling Pathways (7 papers). Claire Fabre collaborates with scholars based in France, United States and Switzerland. Claire Fabre's co-authors include Guido Kroemer, Pierre Fenaux, J. Grosjean, Thomas Braun, Lionel Adès, Paul G. Richardson, Simone Boehrer, Teru Hideshima, Stéphane de Botton and Kenneth C. Anderson and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Claire Fabre

39 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Claire Fabre France 19 752 444 423 234 222 43 1.3k
Elie Traer United States 21 1.1k 1.4× 353 0.8× 666 1.6× 245 1.0× 252 1.1× 64 1.8k
Melanie Braig Germany 15 1.3k 1.7× 450 1.0× 220 0.5× 258 1.1× 197 0.9× 22 1.8k
Valerie Grose United States 6 848 1.1× 246 0.6× 495 1.2× 137 0.6× 374 1.7× 11 1.3k
Helena Jernberg‐Wiklund Sweden 26 1.3k 1.8× 556 1.3× 651 1.5× 255 1.1× 255 1.1× 60 2.0k
Rui-Yu Wang United States 14 964 1.3× 669 1.5× 472 1.1× 336 1.4× 262 1.2× 20 1.7k
Livia Manzella Italy 23 878 1.2× 467 1.1× 456 1.1× 181 0.8× 283 1.3× 68 1.8k
Susan Rice United States 15 589 0.8× 256 0.6× 441 1.0× 330 1.4× 283 1.3× 24 1.2k
Giovanni Roti Italy 23 823 1.1× 312 0.7× 575 1.4× 115 0.5× 159 0.7× 57 1.5k
Vikas Madan Singapore 18 795 1.1× 197 0.4× 308 0.7× 438 1.9× 228 1.0× 33 1.4k
Carmela Gurrieri Italy 18 915 1.2× 393 0.9× 360 0.9× 353 1.5× 102 0.5× 46 1.5k

Countries citing papers authored by Claire Fabre

Since Specialization
Citations

This map shows the geographic impact of Claire Fabre's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Claire Fabre with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Claire Fabre more than expected).

Fields of papers citing papers by Claire Fabre

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Claire Fabre. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Claire Fabre. The network helps show where Claire Fabre may publish in the future.

Co-authorship network of co-authors of Claire Fabre

This figure shows the co-authorship network connecting the top 25 collaborators of Claire Fabre. A scholar is included among the top collaborators of Claire Fabre based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Claire Fabre. Claire Fabre is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Bauer, Todd M., Armando Santoro, Chia‐Chi Lin, et al.. (2023). Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors. Journal for ImmunoTherapy of Cancer. 11(11). e007353–e007353. 24 indexed citations
3.
Wang, Hui Qin, Iain J. Mulford, Fiona A. Sharp, et al.. (2021). Inhibition of MDM2 Promotes Antitumor Responses in p53 Wild-Type Cancer Cells through Their Interaction with the Immune and Stromal Microenvironment. Cancer Research. 81(11). 3079–3091. 43 indexed citations
4.
Bauer, Sebastian, George D. Demetri, Ensar Halilovic, et al.. (2021). Pharmacokinetic–pharmacodynamic guided optimisation of dose and schedule of CGM097, an HDM2 inhibitor, in preclinical and clinical studies. British Journal of Cancer. 125(5). 687–698. 25 indexed citations
5.
Razak, Albiruni R. Abdul, Sebastian Bauer, Cristina Suárez, et al.. (2021). Co-Targeting of MDM2 and CDK4/6 with Siremadlin and Ribociclib for the Treatment of Patients with Well-Differentiated or Dedifferentiated Liposarcoma: Results from a Proof-of-Concept, Phase Ib Study. Clinical Cancer Research. 28(6). 1087–1097. 43 indexed citations
6.
7.
Guerreiro, Nelson, Astrid Jullion, Stéphane Ferretti, Claire Fabre, & Christophe Meille. (2021). Translational Modeling of Anticancer Efficacy to Predict Clinical Outcomes in a First-in-Human Phase 1 Study of MDM2 Inhibitor HDM201. The AAPS Journal. 23(2). 28–28. 14 indexed citations
8.
Decaudin, Didier, Fariba Némati, Mohamed Zerara, et al.. (2020). Preclinical evaluation of drug combinations identifies co-inhibition of Bcl-2/XL/W and MDM2 as a potential therapy in uveal melanoma. European Journal of Cancer. 126. 93–103. 20 indexed citations
9.
Harding, James J., Todd M. Bauer, Daniel Shao-Weng Tan, et al.. (2018). Characterization and phase I study of CLR457, an orally bioavailable pan-class I PI3-kinase inhibitor. Investigational New Drugs. 37(2). 271–281. 7 indexed citations
10.
Fabre, Claire, Naoya Mimura, Kathryn Bobb, et al.. (2012). Dual Inhibition of Canonical and Noncanonical NF-κB Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma. Clinical Cancer Research. 18(17). 4669–4681. 66 indexed citations
11.
Chauhan, Dharminder, Jacob P. Laubach, Claire Fabre, et al.. (2012). New Proteasome Inhibitors in Myeloma. Current Hematologic Malignancy Reports. 7(4). 258–266. 73 indexed citations
12.
Tailler, Maximilien, Lionel Adès, Jean‐Luc Perfettini, et al.. (2008). ATM mediates constitutive NF-κB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia. Oncogene. 28(8). 1099–1109. 60 indexed citations
13.
Fabre, Claire, J. Grosjean, Maximilien Tailler, et al.. (2008). A novel effect of DNA methyltransferase and histone deacetylase inhibitors : NFκB inhibition in malignant myeloblasts. Cell Cycle. 7(14). 2139–2145. 41 indexed citations
14.
Fabre, Claire, Ezgi Tasdemir, Thomas Braun, et al.. (2007). NF-κB inhibition sensitizes to starvation-induced cell death in high-risk myelodysplastic syndrome and acute myeloid leukemia. Oncogene. 26(28). 4071–4083. 79 indexed citations
15.
Boehrer, Simone, Lionel Adès, Thorsten Braun, et al.. (2007). Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study. Blood. 111(4). 2170–2180. 93 indexed citations
16.
Fabre, Claire, Enrique Hernández, Fatiha Chermat, et al.. (2007). P149 Treatment of high risk MDS and AML post-MDS with azacytidine (AZA): current results of the French ATU program. Leukemia Research. 31. S122–S122.
17.
Braun, Thomas, et al.. (2006). Targeting NF-κB in hematologic malignancies. Cell Death and Differentiation. 13(5). 748–758. 137 indexed citations
18.
Fabre, Claire, Thomas Braun, J. Grosjean, et al.. (2006). Inhibition of NEMO, the regulatory subunit of the IKK complex, induces apoptosis in high-risk myelodysplastic syndrome and acute myeloid leukemia. Oncogene. 26(16). 2299–2307. 40 indexed citations
19.
Fabre, Claire, et al.. (2005). Recrudescence of imported falciparum malaria after quinine therapy: potential drug interaction with phenytoin. Transactions of the Royal Society of Tropical Medicine and Hygiene. 99(11). 871–873. 1 indexed citations
20.
Fiasse, René, et al.. (1991). Omeprazole in the treatment of patients with severe reflux oesophagitis not responding to H2-receptor antagonists and ineligible for surgery.. PubMed. 53(5-6). 573–84. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Elie Traer Breakdown of academic impact, for papers by Melanie Braig Breakdown of academic impact, for papers by Valerie Grose Breakdown of academic impact, for papers by Helena Jernberg‐Wiklund Breakdown of academic impact, for papers by Rui-Yu Wang Breakdown of academic impact, for papers by Livia Manzella Breakdown of academic impact, for papers by Susan Rice Breakdown of academic impact, for papers by Giovanni Roti Breakdown of academic impact, for papers by Vikas Madan Breakdown of academic impact, for papers by Carmela Gurrieri
Rankless by CCL
2026